A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease

Trial Profile

A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naive Patients With Late-onset Pompe Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs GZ 402666 (Primary) ; Alglucosidase alfa
  • Indications Glycogen storage disease type II
  • Focus Registrational; Therapeutic Use
  • Acronyms COMET
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Oct 2017 Planned End Date changed from 22 Dec 2020 to 27 May 2021.
    • 18 Oct 2017 Planned primary completion date changed from 22 Dec 2020 to 27 May 2021.
    • 27 Jun 2017 Planned End Date changed from 1 Oct 2020 to 22 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top